3 JPM 2023 roivant Pipeline reflects both ongoing clinical trials and expected upcoming trials. VTAMA has only received FDA approval for psoriasis, not atopic dermatitis. 5 | --- | --- | |----------------------|-----------------| | Psoriasis | $22.3 billion | | Atopic Dermatitis | $12.2 billion | | Crohn's Disease | $9.3 billion | | Ulcerative Colitis | $6.9 billion | | SLE | $3.8 billion | | Rheumatoid Arthritis | $10.2 billion | | | | Indications with active development programs Other indications RVT-3101 ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Jeffrey Kalmus - Head, Strategic Finance Matt Gline - CEO Conference Call Participants David Risinger - SVB Securities Brian Cheng - JPMorgan Corinne Jenkins - Goldman Sachs Alexander Xenakis - Truist Brendan Smith - Cowen Louise Chen - Cantor Neena Bitritto-Garg - Citigroup Douglas Tsao - H.C. Wainwright Yuchen Ding - Jefferies Operator Good day, and thank you for standing by. Welcome to t ...

| --- | --- | --- | --- | |---------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | Roivant | | | | | November 7, 2022 Overview | | | | | | | | | | | | | | Forward-Looking Statements Forward–Looking Statements This presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Our forwardlooking statements include, but are not limi ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Q1 2022 Earnings Conference Call August 15, 2022 8:00 AM ET Company Participants Paul Davis - Head of Communications Matt Gline - CEO Conference Call Participants David Risinger - SVB Securities Dennis Ding - Jefferies Neena Bitritto-Garg - Citi Louise Chen - Cantor Fitzgerald Douglas Tsao - HC Wainwright Corinne Jenkins - Goldman Sachs Brendan Smith - Cowen Alexander Xenakis - Truist Securities Operator Good day, and thank you for standing by. Welcome to the Roivant 1Q 2 ...

| --- | --- | |-------|-------| | | | | | | August 15, 2022 Forward-Looking Statements and Non-GAAP Financial Information Forward–Looking Statements This presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Our forwardlooking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, i ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2021 Earnings Conference Call June 28, 2022 8:00 AM ET Company Participants Paul Davis - Head, Communications Matt Gline - Chief Executive Officer Richard Pulik - Chief Financial Officer Frank Torti - Vant Chair Eric Venker - President and Chief Operating Officer Mayukh Sukhatme - President and Chief Investment Officer Conference Call Participants Dennis Ding - Jefferies Yaron Werber - Cowen Louise Chen - Fitzgerald Neena Bitritto-Garg - Citi David Risinger - SVB Secur ...

ROIVANT SCIENCES Oncology Overview January 2022 of Forward-Looking Statements Forward–Looking Statements and Disclaimer This presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies rega ...

ROIVANT SCIENCES Overview January 2022 O Forward-Looking Statements Forward–Looking Statements and Disclaimer This presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2021 Earnings Conference Call November 15, 2021 8:00 AM ET Company Participants Paul Davis – Head of Communications Matthew Gline – Chief Executive Officer Richard Pulik – Chief Financial Officer Frank Torti – Vant Chair Eric Venker – President and Chief Operating Officer Mayukh Sukhatme – President and Chief Investment Officer Todd Zavodnick – Chief Executive Officer, Dermavant Conference Call Participants Robyn Karnauskas – Truist Securities Douglas Tsao – H.C. Wainw ...

Financial Results and Business Update for the Quarter Ended September 30, 2021 November 15, 2021 Forward-Looking Statements and Non-GAAP Financial Information Forward–Looking Statements Our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Our forward-looking statements include, but are not limited to, statements regard ...